The FDA on Jan. 15 approved Luye Pharma Group’s long-acting injectable Rykindo for the treatment of schizophrenia and bipolar I disorder in adult patients. The Chinese drugmaker will have to face off against Johnson & Johnson’s Risperdal Consta, which has long dominated the market. Like Rykindo, Risperdal Consta is administered every two weeks. J&J also has a newer schizophrenia product line, Invega, that can be administered as little as twice per year. For the treatment of schizophrenia, Risperdal Consta holds covered or better status for 79% of all insured lives under the pharmacy benefit and 90% of lives under the medical benefit.
SOURCE: MMIT Analytics, as of 1/18/23